[Mitochondria as the target for neuroprotectors].
Contemporary methods of treatment of neurodegenerative diseases (NDs) are limited and mainly symptomatic. Despite difference in particular clinical manifestations, NDs have a number of common features, the main of which is death of certain neuron population. The authors suppose that mitochondria and the phenomenon of mitochondrial permeability transition (MPT), playing the key role in cell death, may be a perspective target for the search of drugs with a capability of delaying the neurological deficit associated with NDs. The authors have demonstrated that some neurotoxins which are widely used to model neurodegenerative conditions are able to potentiate or even induce MPT. The neuroprotective effect of widely used cognition-enhancing drugs, such as tacrin, memantine, dimebon, N-acethylserotonine, and extract of Gingko biloba), may also be a result of their interaction with mitochondria. Thus, the search of drugs capable of preventing or breaking the cascade of cell death as a result of MPT suppression and, at the same time, compensating for the impaired brain functions, is very topical.
Shevtsova
E F
EF
Kireeva
E G
EG
Bachurin
S O
SO
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000648:ultrastructure; D016923:Cell Death; D002478:Cells, Cultured; D015259:Dopamine Agents / Q000494:pharmacology / Q000627:therapeutic use; D020441:Ginkgo biloba; D007211:Indoles / Q000627:therapeutic use; D007425:Intracellular Membranes / Q000378:metabolism; D007473:Ion Channels; D015227:Lipid Peroxidation; D008559:Memantine / Q000494:pharmacology / Q000627:therapeutic use; D008928:Mitochondria / Q000187:drug effects* / Q000502:physiology*; D008930:Mitochondria, Liver / Q000187:drug effects / Q000502:physiology; D033681:Mitochondrial Membrane Transport Proteins; D000083162:Mitochondrial Permeability Transition Pore; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D009498:Neurotoxins; D018697:Nootropic Agents / Q000494:pharmacology / Q000627:therapeutic use; D010539:Permeability / Q000187:drug effects; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013619:Tacrine / Q000494:pharmacology / Q000627:therapeutic use
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007211:Indoles; D007473:Ion Channels; D033681:Mitochondrial Membrane Transport Proteins; D000083162:Mitochondrial Permeability Transition Pore; D018696:Neuroprotective Agents; D009498:Neurotoxins; D018697:Nootropic Agents; D010936:Plant Extracts; D013619:Tacrine; C010119:latrepirdine; D008559:Memantine